ERBB2 and breast cancer: Furthermore, immunomonitoring of follow-up patients will reveal whether the immunological parameters identified in this study may be regarded as biomarkers potentially able to predict the clinical outcome of locally advanced HER2-overexpressing BC patients treated with regimens devoid of anthracyclines.